GoodRx Holdings, Inc. Q3 2025 Earnings Recap

GoodRx delivered solid third-quarter performance with a 54% year-over-year revenue growth in its Manufacturer Solutions segment, despite facing challenges from the completion of Rite Aid store closures.

Key Takeaways

• Strong execution led to 54% revenue growth in the Manufacturer Solutions segment, highlighting GoodRx’s effectiveness in improving patient access and affordability.
• Expanded partnerships with manufacturers like Novo Nordisk and Amgen, enhancing the company's cash pricing offerings for key medications.
• Launched new initiatives such as the RxSmartSaver counter solution with Kroger and the Savings Wrangler campaign to strengthen consumer brand trust.
• Ongoing navigation of industry headwinds, particularly from Rite Aid closures, but strategies to recapture displaced users are in progress.
• The evolving U.S. healthcare landscape presents a favorable opportunity for GoodRx, aligning with shifts towards transparency and affordability in drug pricing.